Amylin And Lilly Hope A New Byetta Study Eases Concern Over Drug-Safety Issues

Now, a March 13, 2009 Dow Jones news report, "Study Downplays Risk Of Amylin's Byetta, But Concerns Remain", brings us the latest developments concerning the issue of whether Byetta increases the risk of pancreatitis. According to this report, the professional journal Current Medical Research and Opinion, recently published the findings of an analysis that used an insurance company database to show that neither Byetta nor Januvia — a diabetes drug from Merck & Co. — increased the risk for pancreatitis, which is an inflammation of the pancreas. The report points out that this new analysis was funded by Amylin Pharmaceuticals Inc., the drug company that makes Byetta, and Eli Lilly & Co., which is Amylin's marketing partner for Byetta sales in the U.S.

Read the full article at www.drug